Pheochromocytoma/paraganglioma (PPGL) syndromes associated with polycythemia have previously been described in association with mutations in the von Hippel-Lindau gene. Recently, mutations in the prolyl hydroxylase gene (PHD) 1 and 2 and in the hypoxiainducible factor 2 a (HIF2A) were also found to be associated with multiple and recurrent PPGL. Such patients also presented with PPGL and polycythemia, and later on, some presented with duodenal somatostatinoma. In additional patients presenting with PPGL and polycythemia, no further mutations have been discovered. Because the functional imaging signature of patients with PPGLpolycythemia syndromes is still unknown, and because these tumors (in most patients) are multiple, recurrent, and metastatic, the goal of our study was to assess the optimal imaging approach using 4 different PET radiopharmaceuticals and CT/MRI in these patients. Methods: Fourteen patients (10 women, 4 men) with confirmed PPGL and polycythemia prospectively underwent 68 Ga-DOTATATE (13 patients), 18 F-FDG (13 patients), 18 F-fluorodihydroxyphenylalanine ( 18 F-FDOPA) (14 patients), 18 F-fluorodopamine ( 18 F-FDA) (11 patients), and CT/MRI (14 patients). Detection rates of PPGL lesions were compared between all imaging studies and stratified between the underlying mutations. Results: 18 F-FDOPA and 18 F-FDA PET/CT showed similar combined lesion-based detection rates of 98.7% (95% confidence interval [CI], 92.7%-99.8%) and 98.3% (95% CI, 90.9%-99.7%), respectively. The detection rates for 68 Ga-DOTATATE (35.3%; 95% CI, 25.0%-47.2%), 18 F-FDG (42.3; 95% CI, 29.9%-55.8%), and CT/MRI (60.3%; 95% CI, 48.8%-70.7%) were significantly lower (P , 0.01), irrespective of the mutation status. Conclusion: 18 F-FDOPA and 18 F-FDA are superior to 18 F-FDG, 68 Ga-DOTATATE, and CT/MRI and should be the radiopharmaceuticals of choice in this rare group of patients.
Development of early detection technologies and new therapeutic reagents has significantly improved the quality of treatments in breast cancer patients. However, clinical regression of primary breast tumor by the combination of surgery, hormonal, chemo and radiation therapy does not always extend patients survival. A substantial number of patients develop local and/or distant relapse overtime. The conventional explanation of these observations is that cancer cells acquire resistance during the treatment so their sensitivity to the therapy is reduced. Our previous studies have shown that breast cancer cells in process of invasion deactivate their apoptosis and cell cycle signaling pathways, suggesting they might be intrinsically resistant to radiation and cytotoxic reagents. In this study, we have successfully isolated the cancer cells from four different steps of the metastatic process: the average primary tumor cells, invasive tumor cells (isolated by our in vivo invasion assay), circulating tumor cells collected from blood and metastatic cells separated from lung metastasis. These cells were treated with Tamoxifen, Tamoxifen /Doxorubucin combination and ionizing radiation. Then the percentage of dead and apoptotic cells was quantified to evaluate the response to these different treatments. Interestingly, although these breast cancer cells were isolated from MMTV-PyMT mice that have had no contact with any drug or radiation, the invasive tumor cells and circulating tumor cells were resistant to all three types of treatments, while the primary tumor cells and lung metastatic tumor cells are equally sensitive. To investigate the mechanism behind this observation, we measured the expression of genes in DNA repair pathways and discovered that genes involved in repairing both single and double strand DNA break were transiently upregulated in invasive tumor cells and circulating tumor cells. The DNA repair genes were shown to predict the metastasis development in breast cancer patients when compared to a public microarray data base containing both gene expression and patient metastasis free survival data. We speculate that an elevated DNA repair activity and shutdown of cell cycle and apoptosis together contribute to drug and radiation resistance in the invasive tumor cells. To address this speculation, we chose a small molecule inhibitor of protein phosphatase IIA named LB1.2, which targets the DNA damage/repair pathways and accelerates the cell cycle, and combined it with conventional drug and radiation treatments. LB1.2 completely reversed the resistance of invasive and circulating tumor cells to both drug and radiation treatment mentioned above. In conclusion, we discovered that breast tumor cells in the act of invasion and in circulation are resistant to radiation and drug treatment because of a blocked cell cycle progression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1544.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.